| Literature DB >> 34316657 |
Yohei Mukai1, Hiroyuki Toyoda2, Kenji Miyama2, Yuji Takahashi1.
Abstract
INTRODUCTION: Tube-related adverse events (AEs) occur frequently in patients with Parkinson's disease (PD) receiving levodopa-carbidopa intestinal gel therapy. Endoscopy has become evasive since the beginning of the coronavirus disease 2019 (COVID-19) pandemic. This study aimed to evaluate methods that use the percutaneous endoscopic gastrostomy-jejunostomy (PEG-J) tubes without endoscopy.Entities:
Keywords: Fluoroscopy; Kink; Levodopa-carbidopa intestinal gel; PEG-J tube; Parkinson’s disease
Year: 2020 PMID: 34316657 PMCID: PMC8298846 DOI: 10.1016/j.prdoa.2020.100079
Source DB: PubMed Journal: Clin Park Relat Disord ISSN: 2590-1125
Fig. 1PEG-J tube operation. (A, B–C) Unkinking of the PEG-J tube. (A) The yellow arrow represents the kink site and the interruption of the contrast agent (we termed it “split sign”). (B, C) The PEG-J tube was gently pulled approximately 5–10 cm to release the kink. (D, E–F) Replacement of the PEG-J tube. (D) The red arrow represents the bumper of the PEG tube, which was near the gastrostomy site. (E) We pushed the PEG tube through the gastrostomy site and brought the bumper closer to the pylorus. The red arrow indicates the bumper of the PEG tube. (F) A PEG-J tube was inserted. Folds in the duodenum were imaged with a contrast agent while the tip was in the duodenum. PEG tube, percutaneous endoscopic gastrostomy tube; PEG-J tube, percutaneous endoscopic gastrostomy-jejunostomy tube. (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.)
Fig. 2Releasing the kink in the PEG-J tube and placement of the tube. PEG tube, percutaneous endoscopic gastrostomy tube; PEG-J tube, percutaneous endoscopic gastrostomy-jejunostomy tube.